Skip to main content
AQST
NASDAQ Life Sciences

Aquestive Q3 Revenue Falls 41% to $7.6M; Anaphylm PDUFA Set for March 16, 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.69
Mkt Cap
$486.985M
52W Low
$2.93
52W High
$6.85
52W Position info
26% above low
Off High info
46% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AQST sits 26% above its 52-week low of $2.93.

Summary

Aquestive reported Q3 2026 revenue of $7.6M, down 41% on Suboxone order timing, and a $16.5M net loss, while keeping 2026 guidance unchanged and confirming the Anaphylm PDUFA date of March 16, 2027.


Key Events · Earnings and Guidance · AQST

  • Q3 Revenue Falls 41%

    Total revenues were $7.6M versus $12.8M in Q3 2025, driven by quarterly fluctuation of Suboxone product orders; manufacture and supply revenue fell to $6.7M from $11.5M.

  • Net Loss Widens to $16.5M

    Net loss was $16.5M, or $0.13 per share, versus $15.4M, or $0.14 per share, a year earlier; non-GAAP adjusted EBITDA loss was $12.2M versus $8.6M.

  • Anaphylm PDUFA March 16, 2027

    The FDA accepted the Anaphylm NDA resubmission as a Class 2 response with a PDUFA goal date of March 16, 2027; Health Canada submission is expected in Q4 2026 and an EU filing in Q1 2027.

  • Cash Falls to $90.3M

    Cash and cash equivalents were $90.3M at September 30, 2026, down from $121.2M at December 31, 2025, after the $10M Libervant upfront from Eton Pharmaceuticals in October.


Analysis · AQST · Life Sciences

Revenue dropped 41% year over year to $7.6M because Suboxone orders landed in a different quarter, and the net loss widened to $16.5M from $15.4M. The quarter's real weight sits on Anaphylm: the FDA accepted the resubmission as a Class 2 response with a March 16, 2027 PDUFA date, and the company says launch preparations and a field sales build are on track. Cash fell to $90.3M from $121.2M at year-end, but the $10M Libervant upfront from Eton plus up to $47.5M in milestones and mid-teens royalties adds non-dilutive capital ahead of a potential launch. Full-year guidance was left unchanged at $46-$50M revenue and a $35-$30M adjusted EBITDA loss.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AQST was trading at $3.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487M. The 52-week trading range was $2.93 to $6.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AQST - Latest Insights

AQST
Nov 05, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.66
Real-time Price: $3.79 info
Change: +$0.125 (+3%) info
Market Cap: $473.214M info
AQST
Nov 03, 2026, 4:19 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.79 info
Change: -$0.015 (-0.39%) info
Market Cap: $473.214M info
AQST
Nov 03, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.79 info
Change: +$0.1749 (+5%) info
Market Cap: $473.214M info
AQST
Oct 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.58
Real-time Price: $3.79 info
Change: -$0.795 (-17%) info
Market Cap: $473.214M info
AQST
Oct 14, 2026, 7:21 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.79
Real-time Price: $3.79 info
Change: -$1.01 (-21%) info
Market Cap: $473.214M info